China-based Hangzhou Highlightll Pharmaceutical Co., Ltd has announced the successful completion of a Pre-Series C financing round, raising RMB 150 million (USD 20.5 million). The investment was led by Huajin Capital, Bayland Capital, Infinity Capital, and returning investor Hankang Capital. The funds will be used to enhance the clinical development of late-stage pipelines and the advancement of early-stage pipelines.
Focus on Autoimmune and Neuroinflammatory Diseases
Highlightll Pharma is known for its several small molecules currently undergoing regulatory Phase III studies in autoimmune diseases and inflammation. Additionally, the company has multiple early-stage pipelines targeting neuroinflammation and central nervous system diseases. Among these is TLL041, the world’s first TYK2/JAK1 inhibitor with blood-brain barrier penetrability, which is being developed to treat Alzheimer’s disease and Parkinson’s disease.
Strategic Licensing Agreement with Biohaven
In 2023, TLL041 was licensed to Biohaven for overseas markets in a USD 1 billion deal. This strategic partnership highlights the potential of Highlightll Pharma’s innovative drug candidates and their global market appeal.-Fineline Info & Tech
